Therapeutic Oligonucleotides Transcriptional and Translational Strategies for Silencing Gene Expression, Volume 1058

by Cho-Chung, Yoon S.; Gewirtz, Alan M.; Stein, Cy A.

• ISBN13: 9781573316095
• ISBN10: 1573316091
• Edition: 1st
• Format: Paperback
• Copyright: 2005-12-23
• Publisher: Wiley-Blackwell

Summary

The potential for the development of therapeutic oligonucleotides into clinical medicines and their use as basic research tools are explored in this volume, which is the proceedings of the 7th NIH Symposium on Therapeutic Oligonucleotides. The focus is on antisense, RNAi, triple-helix, gene repair, DNA chips, and CpG immune modulatory oligonucleotides.Specific chapters address designing better siRNAs, splice switching oligonucleotides, selective delivery of oligonucleotides, and medicinal drugs by receptor-mediated endocytosis, development of a function overriding siRNA silencing in mammalian cells, transcription factor decoys, and modified oligonucleotide hybridization and genetic insertion.NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit www.nyas.org/membership/main.asp for more information about becoming a member.

Author Biography

Yoon S. Cho-Chung and Alan M. Gewirtz are the authors of Therapeutic Oligonucleotides: Transcriptional and Translational Strategies for Silencing Gene Expression, Volume 1058, published by Wiley.

Table of Contents

Introduction

Kill the Messenger

Knock-down of the Cytoprotective Gene, Clusterin, to Enhance Hormone and Chemosensitivity in Prostate and Other Cancers

Recognition of Chromosomal DNA in Human Cells by Peptide Nucleic Acids and Small Duplex RNAs

Antisense and siRNA: Chemistry, Sequence Specificity, and Target Validation

Design and Development of Thermolytic DNA Oligonucleotide Prodrugs

Rationally Targeted, Conformationally Constrained, Oxetane-Modified Oligonucleotides Demonstrate Efficient Gene-Silencing Activity in a Cellular System

Delivery Cellular and Phenotype Effect of Silencing Agents

In Vivo Potentialities Andrei Maksimenko, Valerie Polard, Marie Villemeur, Hind Elhamess, Patrick Couvreur, Jean-Remi Bertrand, Malam Aboubakar, Marina Gottikh, and Claude Malvy of EWS-Fli-1 Targeted Antisense Oligonucleotides-Nanospheres Complexes

Endo-Porter: A Novel Reagent for Safe, Effective Delivery of Substances into Cells

Tumor Reversion: Protein Kinase A Isozyme Switching

Immune Modulation of and Resistance to Silencing Agents

Therapeutic Potential of Oligonucleotides Expressing Immunosuppressive TTAGGG Motifs

Breaking Tolerance to Tumors with Dendritic Cell-Based Immunotherapy

Development of Resistance to RNAi in Mammalian Cells

Transcription Silencing by Nucleic Acid Molecules

The Development of Bioactive Triple Helix-Forming Oligonucleotides

Transcription Factor Decoys: A New Model for Disease Intervention

DNA Damage Produced by 125I-Triplex-Forming Oligonucleotides as a Measure of Their Succesful Delivery into Cell Nuclei

Targeted Genome Modification via Triple Helix Formation

Functional Genomics-Antisense/RNAi

"Promoter Array" Studies Identify Cohorts of Genes Directly Regulated by Methylation, Copy Number Change, or Transcription Factor Binding in Human Cancer Cells

Application of Expression Genomics for Predicting Treatment Response in Cancer

Stability Regulation of mRNA and the Control of Gene Expression

Chemosensitivity Enhancement by Antisense and RNAi

Novel MDM2 p53-Independent Functions Identified through RNA Silencing Technologies

Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/ GEM?640

Nucleic Acid T

Table of Contents provided by Publisher. All Rights Reserved.